Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Products under Development by Stage of Development | 7 | 1 |
| Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Products under Development by Therapy Area | 8 | 1 |
| Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Products under Development by Indication | 9 | 1 |
| Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Products under Development by Companies | 12 | 2 |
| Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Therapeutics Assessment | 14 | 6 |
| Assessment by Monotherapy/Combination Products | 14 | 1 |
| Assessment by Mechanism of Action | 15 | 1 |
| Assessment by Route of Administration | 16 | 2 |
| Assessment by Molecule Type | 18 | 2 |
| Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Companies Involved in Therapeutics Development | 20 | 2 |
| Noxxon Pharma AG | 20 | 1 |
| Pieris Pharmaceuticals, Inc. | 21 | 1 |
| Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Drug Profiles | 22 | 9 |
| lexaptepid pegol Drug Profile | 22 | 3 |
| M-009 Drug Profile | 25 | 1 |
| M-012 Drug Profile | 26 | 2 |
| PRS-080 Drug Profile | 28 | 2 |
| Recombinant Protein for Iron Overload Disorders Drug Profile | 30 | 1 |
| Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Dormant Projects | 31 | 1 |
| Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Discontinued Products | 32 | 1 |
| Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Featured News &Press Releases | 33 | 10 |
| May 09, 2016: Merganser Biotech Announces Issuance of U.S. Patent 9,315,545 Covering Development Compound M012 | 33 | 1 |
| May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases | 33 | 1 |
| Feb 24, 2016: Merganser Biotech Initiates First Clinical Trial | 34 | 1 |
| Dec 07, 2015: Pieris Pharmaceuticals Presents Clinical Data for its Hepcidin Antagonist Program, PRS-080, at the 2015 American Society Of Hematology Annual Meeting | 34 | 1 |
| Nov 05, 2015: Pieris Pharmaceuticals Announces Presentation Of Clinical Data For Its Hepcidin Antagonist Program, Prs-080, At The 2015 American Society Of Hematology Annual Meeting | 35 | 1 |
| Jun 10, 2015: Pieris Pharmaceuticals Completes Dosing of Healthy Volunteers in Phase I Clinical Trial for Anticalin Program in Anemia | 36 | 1 |
| Dec 11, 2014: Pieris Initiates Phase I Clinical Trial for Anticalin to Treat Anemia | 36 | 1 |
| Jul 31, 2014: NOXXON Pharma Initiates Phase IIa Study Of Anti-Hepcidin Spiegelmer Lexaptepid Pegol (NOX-H94) In Dialysis Patients With EPO-hypo-responsive Anemia | 37 | 1 |
| Apr 08, 2014: Anti-Hepcidin Spiegelmer Lexaptepid Pegol Increases Hemoglobin in Subset of Anemic Patients in Pilot Phase IIa Study | 37 | 1 |
| Dec 06, 2012: Noxxon Pharma To Present Phase I Data Of NOX-H94 At ASH Annual Meeting 2012 | 38 | 1 |
| Dec 04, 2012: Noxxon Pharma Initiates Phase IIa Clinical Trial Of Anti-hepcidin Spiegelmer NOX-H94 | 38 | 1 |
| Dec 13, 2011: Pieris Presents Preclinical Data For PRS-080 Hepcidin Antagonist Anticalin Program At ASH Annual Meeting | 39 | 1 |
| Nov 01, 2011: UCLA scientists design experimental treatment for iron-overload diseases | 40 | 1 |
| Sep 06, 2011: NOXXON Initiates Phase I Clinical Trial Of NOX-H94 For Anemia Of Chronic Disease | 41 | 1 |
| May 23, 2011: Pieris Announces Preclinical In Vitro And In Vivo Data For Anticalin PRS-080 Hepcidin Antagonist Drug Program | 42 | 1 |
| Appendix | 43 | 2 |
| Methodology | 43 | 1 |
| Coverage | 43 | 1 |
| Secondary Research | 43 | 1 |
| Primary Research | 43 | 1 |
| Expert Panel Validation | 43 | 1 |
| Contact Us | 43 | 1 |
| Disclaimer | 44 | 1 |